Filing Details
- Accession Number:
- 0001415889-23-011881
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-04 19:32:15
- Reporting Period:
- 2023-08-02
- Accepted Time:
- 2023-08-04 19:32:15
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 855654 | Immunogen Inc. | IMGN | Pharmaceutical Preparations (2834) | 042726691 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1586965 | J Mark Enyedy | C/O Immunogen, Inc. 830 Winter Street Waltham MA 02451 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-08-02 | 995,157 | $4.55 | 1,436,606 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-02 | 986,521 | $17.45 | 450,085 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-08-02 | 8,636 | $18.15 | 441,449 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-08-03 | 2,760 | $5.25 | 444,209 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-03 | 1,017,240 | $4.55 | 1,461,449 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-03 | 1,020,000 | $16.61 | 441,449 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-08-04 | 782,240 | $5.25 | 1,223,689 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-04 | 21,978 | $4.55 | 1,245,667 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-08-04 | 300,000 | $5.65 | 1,545,667 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-08-04 | 992,397 | $16.96 | 553,270 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-02 | 995,157 | $0.00 | 995,157 | $4.55 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-03 | 2,760 | $0.00 | 2,760 | $5.25 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-03 | 831,147 | $0.00 | 831,147 | $4.55 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-03 | 186,093 | $0.00 | 186,093 | $4.55 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-04 | 300,000 | $0.00 | 300,000 | $5.65 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-04 | 782,240 | $0.00 | 782,240 | $5.25 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-08-04 | 21,978 | $0.00 | 21,978 | $4.55 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 382,968 | 2022-11-14 | 2030-02-07 | No | 4 | M | Direct |
| 782,240 | 2020-01-31 | 2029-01-31 | No | 4 | M | Direct |
| 218,853 | 2021-02-07 | 2030-02-07 | No | 4 | M | Direct |
| 196,875 | 2022-11-14 | 2030-02-07 | No | 4 | M | Direct |
| 0 | 2017-05-16 | 2026-05-16 | No | 4 | M | Direct |
| 0 | 2020-01-31 | 2029-01-31 | No | 4 | M | Direct |
| 196,875 | 2021-02-07 | 2030-02-07 | No | 4 | M | Direct |
Footnotes
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.14 to $18.11, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $17.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
- The options vested in installments upon the satisfaction of certain performance criteria.
- Exercisable in three equal installments over three years starting on the first year anniversary of the grant.
- Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
- Exercisable in four equal installments over four years starting on the first year anniversary of the grant.
Billionaire Hedge Funds
